Collaboration will Bring Industry-Leading Purification Ligands to High Throughput Biotherapeutic Process Development

The aim of the collaboration is to develop new tools and innovative solutions to purify and precisely quantify biotherapeutic antibodies in complex samples (such as cell culture supernatant and serum), a critical step in the manufacture of new biotherapeutics.  BAC will contribute their proprietary CaptureSelect® Antibody Toolbox affinity ligands, based on Camelid single-chain antibody fragments. The unique properties of these ligands, such as high selectivity and distinctive binding characteristics, provide increased flexibility in the purification process of any antibody format. BAC CEO, Dr. Laurens Sierkstra comments, “By combining BAC’s solutions for antibody purification with the AssayMAP high-throughput chromatography platform we enable researchers to optimize production and purification processes for their lead molecules early in the development process.”

BioSystem Development contributes the AssayMAP micro-chromatography platform, a patented cartridge separation system bridging complex chemistries with high-throughput, high-precision environments. BSD’s Founder and CEO Scott Fulton stated, “This collaboration provides a scalable format with the CaptureSelect purification technology. We are starting with the CaptureSelect Fab kappa and Human Fc ligands to enable parallel, high-throughput purification and analysis of antibodies and fusions from any source, bringing this technology to bioprocess research and development.”